VYNE Therapeutics (VYNE) Receivables (2017 - 2023)
VYNE Therapeutics (VYNE) posted Receivables of $250000.0 for Q3 2023, up 6.84% on a QoQ basis from $234000.0 in Q2 2023, and down 46.92% year-over-year from $471000.0 in Q3 2022.
VYNE Therapeutics (VYNE) Receivables (2017 - 2023) Analysis & Trends
VYNE Therapeutics' Receivables history runs 7 years deep, the most recent figure standing at $250000.0 for Q3 2023.
- Quarterly Receivables fell 46.92% year-over-year to $250000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $250000.0 (down 46.92% YoY) and the FY2022 annual result came in at $173000.0, down 98.68% from the prior year.
- Receivables was $250000.0 for Q3 2023 at VYNE Therapeutics, up from $234000.0 in the prior quarter.
- Across five years, Receivables topped out at $21.6 million in Q4 2020 and bottomed at $105000.0 in Q1 2023.
- A 5-year average of $7.9 million and a median of $4.4 million in 2020 frame the typical range for Receivables.
- Annual changes were most pronounced in 2020 — Receivables surged 15914.07% — and 2022, when it tumbled 98.68%.
- VYNE Therapeutics' Receivables stood at $135000.0 in 2019, then jumped by 15914.07% to $21.6 million in 2020, then plunged by 39.48% to $13.1 million in 2021, then tumbled by 98.68% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
- Business Quant data shows VYNE's Receivables at $250000.0 in Q3 2023, $234000.0 in Q2 2023, and $105000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 250,000.00 |
| Jun 30, 2023 | 234,000.00 |
| Mar 31, 2023 | 105,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 471,000.00 |
| Jun 30, 2022 | 304,000.00 |
| Mar 31, 2022 | 535,000.00 |
| Dec 31, 2021 | 13.08 Mn |
| Sep 30, 2021 | 17.38 Mn |
| Jun 30, 2021 | 18.47 Mn |
| Mar 31, 2021 | 18.86 Mn |
| Dec 31, 2020 | 21.62 Mn |
| Sep 30, 2020 | 16.79 Mn |
| Jun 30, 2020 | 10.41 Mn |
| Mar 31, 2020 | 8.33 Mn |
| Dec 31, 2019 | 135,000.00 |
| Jun 30, 2018 | 93,000.00 |
| Mar 31, 2018 | 234,000.00 |
| Dec 31, 2017 | 786,000.00 |